Innovations in design and delivery of chemotherapy for brain tumors

被引:24
作者
Gururangan, S [1 ]
Friedman, HS
机构
[1] Duke Univ, Med Ctr, Brain Tumor Ctr, Dept Pediat Clin Serv, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Brain Tumor Ctr, Dept Neurooncol, Durham, NC 27710 USA
关键词
D O I
10.1016/S1052-5149(02)00031-X
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Although surgery and radiotherapy long have been established as treatment modalities of patients with brain tumors, the role of chemotherapy in such patients is far from certain. Nevertheless, it has continued to play a significant part in the therapeutic armamentarium against these tumors in the last several decades and might have contributed to disease stabilization and cure of some patients with brain tumors. Concurrently, it has become obvious that a significant proportion of patients with brain tumors also suffer progressive disease during or following chemotherapy. The causes for such therapeutic failure have been explored and reported extensively. Invariably, the lack of response to chemotherapy has been caused by the presence of the blood-brain barrier and drug resistance. This article initially discusses factors that contribute to chemotherapy failure followed by a discussion of recent advances in design and delivery of chemotherapy that have attempted to overcome some of these obstacles and improve antitumor responses and survival in patients with brain tumors.
引用
收藏
页码:583 / +
页数:16
相关论文
共 87 条
  • [1] Bartus RT, 2000, J PHARMACOL EXP THER, V293, P903
  • [2] Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: Implications for treating newly emerging tumor colonies
    Bartus, RT
    Snodgrass, P
    Dean, RL
    Kordower, JH
    Emerich, DF
    [J]. EXPERIMENTAL NEUROLOGY, 2000, 161 (01) : 234 - 244
  • [3] BATCHELOR TT, 2001, CANC CHEMOTHERAPY BI, P657
  • [4] Intracellular localization and intercellular heterogeneity of the human DNA repair protein O-6 methylguanine-DNA methyltransferase
    Belanich, M
    Randall, T
    Pastor, MA
    Kibitel, JT
    Alas, LG
    Dolan, ME
    Schold, SC
    Gander, M
    Lejeune, FJ
    Li, BFL
    White, AB
    Wasserman, P
    Citron, ML
    Yarosh, DB
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) : 547 - 555
  • [5] New cytotoxic drugs for intrathecal administration
    Blaney, SM
    Poplack, DG
    [J]. JOURNAL OF NEURO-ONCOLOGY, 1998, 38 (2-3) : 219 - 223
  • [6] Neoplastic meningitis: diagnosis and treatment considerations
    Blaney, SM
    Poplack, DG
    [J]. MEDICAL ONCOLOGY, 2000, 17 (03) : 151 - 162
  • [7] REDUCTION IN CENTRAL NERVOUS-SYSTEM LEUKEMIA WITH A PHARMACOKINETICALLY DERIVED INTRATHECAL METHOTREXATE DOSAGE REGIMEN
    BLEYER, WA
    COCCIA, PF
    SATHER, HN
    LEVEL, C
    LUKENS, J
    NIEBRUGGE, DJ
    SIEGEL, S
    LITTMAN, PS
    LEIKIN, SL
    MILLER, DR
    CHARD, RL
    HAMMOND, GD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (05) : 317 - 325
  • [8] Epidemiologic impact of children with brain tumors
    Bleyer, WA
    [J]. CHILDS NERVOUS SYSTEM, 1999, 15 (11-12) : 758 - 763
  • [9] Anticancer drug resistance in primary human brain tumors
    Bredel, M
    [J]. BRAIN RESEARCH REVIEWS, 2001, 35 (02) : 161 - 204
  • [10] INTERSTITIAL CHEMOTHERAPY WITH DRUG POLYMER IMPLANTS FOR THE TREATMENT OF RECURRENT GLIOMAS
    BREM, H
    MAHALEY, S
    VICK, NA
    BLACK, KL
    SCHOLD, SC
    BURGER, PC
    FRIEDMAN, AH
    CIRIC, IS
    ELLER, TW
    COZZENS, JW
    KENEALY, JN
    [J]. JOURNAL OF NEUROSURGERY, 1991, 74 (03) : 441 - 446